Furuya-Kanamori et al. [20] used eight VEGF inhibitors, namely, axitinib, lenvatinib, nintedanib, pazopanib, regorafenib, sunitinib, sorafenib, and vandetanib, in patients with different types of cancer; however, despite evidence supporting an increased risk of bleeding with sunitinib treatment, none of these VEGF inhibitors were associated with cardiovascular events, including thrombotic events, myocardial infarction, stroke, venous thrombosis, PE, left ventricular dysfunction, and QT prolongation. This evidence concerns the gene VEGFA and stroke disorder.